AXITINIB IN ADVANCED / METASTATIC RENAL CELL CARCINOMA - A NON-INTERVENTIONAL STUDY OF REAL WORLD TREATMENT OUTCOMES IN PATIENTS RECEIVING 2ND LINE AXITINIB AFTER 1ST LINE SUNITINIB (ADONIS)
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ADONIS
- Sponsors Pfizer
- 12 Oct 2019 Planned End Date changed from 20 Jul 2019 to 1 May 2021.
- 12 Oct 2019 Planned primary completion date changed from 20 Jul 2019 to 1 May 2021.
- 16 Feb 2019 Results assessing the real-world experience with first-line sunitinib treatment in patients with mRCC (Data cutoff: May 31, 2018; n=467) presented at the 2019 Genitourinary Cancers Symposium